Key result
Maternal serum MMP-3 levels were elevated in preeclamptic women with fetal growth restriction (mean 52.81 ng/mL) compared to healthy controls (33.50 ng/mL) and normotensive women with FGR.
Why the study?
The study aimed to assess the relationship between maternal serum matrix metalloproteinase-3 levels and pregnancy complications involving foetal growth restriction, whether idiopathic or during preeclampsia.
Are matrix metalloproteinase-3 (MMP-3) levels associated with foetal growth restriction and preeclampsia in pregnant women?
Population
245 pregnant women including those with idiopathic FGR, severe preeclampsia, and healthy controls
Comparison
Idiopathic FGR vs severe preeclampsia with/without FGR vs healthy controls
Authors
Loading...
May flag FGR risk in preeclampsia but should not change practice; leaves open its value as a biomarker.
Observational (n=245)
Are matrix metalloproteinase-3 (MMP-3) levels associated with foetal growth restriction and preeclampsia in pregnant women?
Absolute Event Rate: 52.81% vs 33.5%
Elevated MMP-3 levels in preeclamptic women may indicate a higher risk for fetal growth restriction and lower birth weight.
Laskowska et al. (2023) conducted an observational in Preeclampsia and foetal growth restriction (n=245). Preeclampsia with foetal growth restriction vs. Healthy pregnancy and normotensive pregnancy with idiopathic foetal growth restriction was evaluated on Matrix metalloproteinase-3 (MMP-3) levels in maternal circulation. Maternal serum MMP-3 levels were elevated in preeclamptic women with fetal growth restriction (mean 52.81 ng/mL) compared to healthy controls (33.50 ng/mL) and normotensive women with FGR.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: